Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Taiho Oncology, Inc.
Taiho Oncology, Inc.
Adela, Inc
OncoNano Medicine, Inc.
Immunitas Therapeutics
ModernaTX, Inc.
Incyte Corporation
Tempus AI
Celgene
Intensity Therapeutics, Inc.
RAPT Therapeutics, Inc.
VitaMed Research LLC
Sanguine Biosciences
Presage Biosciences
Eisai Inc.
Fate Therapeutics
Atara Biotherapeutics
Seagen Inc.
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Presage Biosciences
Incyte Corporation
Celgene
Celgene
Tocagen Inc.
Amgen
Lytix Biopharma AS
Valerio Therapeutics
Altor BioScience
Exelixis